Latham & Watkins Advises on Gilead Sciences’ US$3 Billion Senior Unsecured Notes Offering

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, announced the pricing of senior unsecured notes in an aggregate principal amount of US$3 billion in an underwritten, registered public offering, consisting of US$500 million of 4.250% senior notes maturing in 2028; US$1 billion of 4.400% senior notes maturing in 2029; US$1 billion of 4.600% senior notes maturing in 2031; and US$500 million of 4.900% senior notes maturing in 2034. The offering is expected to close on May 20, 2026, subject to customary closing conditions.

Latham & Watkins LLP represents the underwriters in the offering with a Capital Markets team led by partners Greg Rodgers and Chuck Cassidy, with associates Will Coughlin, Steve Hess, and Alondra Tlatelpa. Advice was also provided on tax matters by partner Bora Bozkurt, with associate Jack Santoro; on healthcare matters by partner Betty Pang; on intellectual property matters by counsel Robert Yeh, with associate Patrick Chew; on data privacy and cybersecurity matters by partner Heather Deixler, with associate Sarah Zahedi; on FDA regulatory matters by partner Ben Haas and counsel Chad Jennings, with associate Meryl Bartlett; on compliance matters by partner Kevin Chambers and counsel Ruchi Gill, with associate Matthew Crawford; and on EU/UK regulatory matters by partner Eveline Van Keymeulen, with associate Grégoire Paquet.